Scarica l'app Stockscreener
1.31
2.96%
-0.04
Dopo l'orario di chiusura:
1.31
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - stocktwits.com
BlackRock Inc. Buys Shares of 7,791,869 Neumora Therapeutics, Inc. $NMRA - MarketBeat
Insiders Sold Neumora Therapeutics Prematurely At US$2.29 With Stock Trading Higher - simplywall.st
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
2,559,090 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by ICONIQ Capital LLC - MarketBeat
Neumora Therapeutics COO Aurora disposes of $269,966 in stock - in.investing.com
Daljit Singh Aurora Sells 21,055 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat
Neumora Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Aurora Daljit Singh - Moomoo
Neumora Therapeutics (NMRA) grants chair 500K stock options - Stock Titan
Neumora Therapeutics (NASDAQ: NMRA) officer plans 41,608-share sale after August trades - Stock Titan
Mizuho maintains Outperform on Neumora, cuts target to $4 - scanx.trade
Neumora (NASDAQ: NMRA) officer plans cashless sale of 134K shares - Stock Titan
Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock - Investing.com
Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock By Investing.com - Investing.com South Africa
Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 31,000 Shares - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 34,987 Shares - MarketBeat
Neumora Therapeutics (NMRA) insider plans new stock sale after $329K in recent trades - Stock Titan
Q3 EPS Estimate for Neumora Therapeutics Lifted by Analyst - MarketBeat
Neumora Therapeutics, Inc. Stock 12‑Month Price Target Raised to $6.67, Implies 307% Upside - TradingView
Neumora (NASDAQ: NMRA) insider to sell 69K more shares - Stock Titan
Neumora Therapeutics, Inc. (NMRA) Receives a Buy from RBC Capital - The Globe and Mail
Neumora (NASDAQ: NMRA) to sell 146K shares via Merrill Lynch - Stock Titan
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
1,849,445 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by Johnson & Johnson - MarketBeat
RBC Capital maintains Outperform on Neumora, cuts target to $5 - scanx.trade
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Neumora Therapeutics Appoints Joshua Pinto as CEO and Releases Q2 2026 Financial Results - Kalkine Media
Neumora Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
8-K: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updatemoomoo - moomoo.com
Neumora Therapeutics Cuts Q2 Net Loss to $41.3M on Lower R&D Spend - Minichart
Neumora Appoints New CEO as Q2 Net Loss Narrows to $43.1M - Minichart
Form 8K Neumora Therapeutics Inc For: 14 August By Investing.com - Investing.com Australia
Levi & Korsinsky investigates Neumora after trial failure - scanx.trade
Neumora Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neumora Therapeutics Q2 EPS of $(0.23) beats estimates - scanx.trade
Neumora Therapeutics 2Q 2026: Net loss $(43.1M), EPS $(0.23) — 10-Q Summary - TradingView
Neumora Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Neumora Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
NMRA: Pipeline advanced, net loss narrowed, and cash runway extends into Q3 2027 - TradingView
Neumora Therapeutics Reports Second Quarter 2026 Results and Advances Pipeline Amid Leadership Changes - Quiver Quantitative
Neumora Names Joshua Pinto CEO as 2026 Clinical Milestones Near - Stock Titan
Neumora Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Neumora Therapeutics (NMRA) Holds Above Key Support at $1.54 After Minor SlideForce Index - dars.gov.et
NMRA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutic - The National Law Review
Neumora Therapeutics (NMRA) Gains 2.48% as Biotech Stock Holds Above $1.57 SupportOBV Trend Line - vinanet.vn
Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Why Is BioAge Labs Stock Sinking Friday? - Benzinga
Neumora Therapeutics, Inc. Revenue Breakdown – NASDAQ:NMRA - TradingView
Neumora Therapeutics Inc. (NMRA) Q1 2026 Earnings: Narrower-Than-Expected Loss on Cost Discipline, Shares SlipMargin Compression Risk - dars.gov.et
Neumora Therapeutics (NMRA) Expected to Release Earnings on Wednesday - MarketBeat
H.C. Wainwright reiterates Neumora stock rating on positive toxicology data By Investing.com - Investing.com Nigeria
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):